 |
|
Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women’s Health Initiative
Sumit R. Majumdar, MD, MPH;
Elizabeth A. Almasi;
Randall S. Stafford, MD, PhD
JAMA. 2004;292:1983-1988.
Context Little is known about how the pharmaceutical industry responds to evidence of harm associated with its products, such as the publication in July 2002 of the Women’s Health Initiative Estrogen Plus Progestin Trial (WHI E+P) report demonstrating that standard-dose Prempro produced significant harm and lacked net benefits.
Objective To examine pharmaceutical industry response to the WHI E+P results by analyzing promotional expenditures for hormone therapy before and after July 2002.
Design and Setting Nationally representative and prospectively collected longitudinal data (January 2001 through December 2003) on prescribing and promotion of hormone therapies were obtained from IMS Health and Consumer Media Reports.
Main Outcome Measures Trends in quarterly prescriptions for hormone therapy and expenditures on 5 modes of drug promotion: samples, office-based detailing, hospital-based promotion, journal advertisements, and direct-to-consumer advertising.
Results Prior to the WHI E+P report, prescribing rates and promotional spending for hormone therapy were stable. In the quarter before the WHI E+P report (April-June 2002), 22.4 million prescriptions for hormone therapy were dispensed and $71 million was spent on promotion (in annual terms, $350 per year per US physician). Within 9 months of the report’s publication (quarter 1 of 2003), there was a 32% decrease in hormone therapy prescriptions, and a nadir had been reached for promotional spending (37% decrease compared with pre-WHI E+P levels). Spending decreased for all promotional activities and most hormone therapies. Overall, the greatest declines were for samples (36% decrease as of quarter 1 of 2003) and direct-to-consumer advertising (100% decrease). The greatest declines in promotion occurred for standard-dose Prempro (61% decrease as of quarter 1 of 2003), the agent implicated by the WHI E+P report. More recently, promotional efforts have increased, particularly for lower-dose Prempro, a resurgence associated with modestly increased prescriptions for this newer agent.
Conclusions Concordant with its widespread use, hormone therapy was among the most heavily promoted medications prior to the WHI E+P report. Following reporting of the evidence of harm from this trial, there was a substantial decline in promotional spending for hormone therapy, particularly for the agents most directly implicated in the trial. Interrelated with the impact of the trial results themselves and the ensuing media coverage, reduced promotion may have contributed to a substantial decline in hormone therapy prescriptions.
Author Affiliations: Department of Medicine, University of Alberta, Edmonton (Dr Majumdar); Stanford Prevention Research Center, Program on Prevention Outcomes and Practices, Stanford University School of Medicine, Stanford, Calif (Ms Almasi and Dr Stafford).
Corresponding Author: Randall S. Stafford, MD, PhD, Stanford Prevention Research Center, Program on Prevention Outcomes and Practices, Hoover Pavilion, Stanford University School of Medicine, Stanford, CA 94305 (rstafford{at}stanford.edu).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents
Berger et al.
CMAJ 2008;178:1660-1668.
ABSTRACT
| FULL TEXT
Factors Associated with Obstetrician-Gynecologists' Response to the Women's Health Initiative Trial of Combined Hormone Therapy
Power et al.
Med Decis Making 2008;28:411-418.
ABSTRACT
Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections
Krieger
Int J Epidemiol 2008;37:627-637.
ABSTRACT
| FULL TEXT
Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer
Rossing et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2548-2556.
ABSTRACT
| FULL TEXT
Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
Glass et al.
JNCI J Natl Cancer Inst 2007;99:1152-1161.
ABSTRACT
| FULL TEXT
Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing
Dorval et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:157-160.
ABSTRACT
| FULL TEXT
Failure to Adopt Beneficial Therapies Caused by Bias in Medical Evidence Evaluation.
Aberegg et al.
Med Decis Making 2006;26:575-582.
ABSTRACT
Changes in u.s. Prescribing patterns of menopausal hormone therapy, 2001-2003.
Hing and Brett
Obstet Gynecol 2006;108:33-40.
ABSTRACT
| FULL TEXT
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Circulation 2006;113:e873-e923.
ABSTRACT
| FULL TEXT
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Stroke 2006;37:1583-1633.
ABSTRACT
| FULL TEXT
How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins
Austin et al.
The Annals of Pharmacotherapy 2006;40:1047-1051.
ABSTRACT
| FULL TEXT
Treatment of Menopausal Symptoms in Family Medicine Settings following the Women's Health Initiative Findings
The Florida Behavioral Health Research Consortium et al.
J Am Board Fam Med 2006;19:122-131.
ABSTRACT
| FULL TEXT
Sex hormones and the genesis of autoimmunity.
Ackerman
Arch Dermatol 2006;142:371-376.
ABSTRACT
| FULL TEXT
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives
Krieger et al.
J. Epidemiol. Community Health 2005;59:740-748.
ABSTRACT
| FULL TEXT
Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada
Austin and Mamdani
Circulation 2005;112:1296-1300.
ABSTRACT
| FULL TEXT
Estrogen Plus Progestin, Benefits and Risks: The "Women's Health Initiative" Trials
Keller and Lemberg
Am J Crit Care 2005;14:157-160.
FULL TEXT
|
